CD38 and Miyoshi myopathy: In this large, real-world, retrospective, multi-center cohort study, we demonstrate that patients with MM relapsing on anti-CD38 mAb-containing regimens had poor outcomes when treated with SoC therapies, with a median PFS and OS of 4.6 months and 13.3 months from initiation of subsequent SoC treatment, respectively.